Navigation Links
CIGNA Medical Group Selects Allscripts for Electronic Health Record
Date:2/25/2008

Phoenix Multi-Specialty Group Practice to Connect 170 Clinicians with

Web-hosted EHR

ORLANDO, Fla., Feb. 25 /PRNewswire-FirstCall/ -- Direct from the HIMSS 2008 Conference and Exhibition, Allscripts, the leading provider of clinical software, connectivity and information solutions that physicians use to improve health care, today announced that CIGNA Medical Group (CMG) has selected Allscripts as their Electronic Health Record (EHR) provider for their primary care and specialty physicians. An EHR is a highly secure web-based software application that allows clinicians to record each and every aspect of a patient's health record in real time in an electronic format. A division of CIGNA HealthCare of Arizona, Inc., CMG is one of the largest multi-specialty group practices in metropolitan Phoenix with more than 170 clinicians in 21 offices.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061005/ALLSCRIPTSLOGO-b )

The Electronic Health Record from Allscripts replaces paper recordkeeping by allowing clinicians to complete everyday clinical tasks such as prescribing medications, ordering and viewing laboratory tests, and documenting patient care in real time in an electronic format.

"Our EHR choice is designed to help improve quality by facilitating our physicians' practice of following evidence-based medical practices, using electronic, rather than paper, records," said Bob Carroll, vice president of operations for CIGNA HealthCare of Arizona.

Allscripts will connect CMG physicians and other caregivers to laboratories, pharmacies, insurers and other key healthcare stakeholders, while delivering secure, immediate access to patient information at the point of care -- whether in the office, at the hospital or remotely. Important features of the Electronic Health Record include robust tools for documentation and orde
'/>"/>

SOURCE Allscripts
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolyti...s" or the "Company") today announced updated resul...) in patients with sarcomas metastatic to the lung...ctive Tissue Oncology Society Meeting held in Miam...ster presentation, entitled "A Phase II Study of I...
(Date:11/5/2009)...TRANSPORTATION -- Gone hybrid . . . , Fuel eco...es are now posted at the www.fueleconomy.gov web...ed and maintains for the U.S. Department of Energy...e of the top 10 vehicles on the best fuel economy ... (51 MPG city; 48 highway). "This list proves that...
(Date:11/5/2009)... PARSIPPANY, N.J., Nov. 5 DSM Phar...de a manufacturing alliance with Galenix, Saint Je...d commercial scale manufacturing partner for Galen...M and Galenix will collaborate on business develop...ery technologies, based on the strength of Galenix...
(Date:11/5/2009)... Conference Call on Thursday, November 5, 2009 at ...OUVER Nov. 5 /PRNewswire-FirstCall/ - OncoGenex Ph... (NASDAQ: OGXI ) today reported unaudited financi...nded September 30, 2009 and reviewed the Company,s...he following consolidated results reflect the oper...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8
...chnologies,Corporation, a leader in tumor-targeted...l European patents for the platform targeting tech...on gene delivery to primary cancers and,metastatic...h profound,demonstrations of clinical benefit and ...Epeius Biotech continues to lead the field of clin...
...siva,Inc. (Nasdaq: ANSV ) today announced top-li...ng Adlea(TM), its long-acting, non-opioid analgesi...dpoint of reducing post-surgical,pain versus place..., or total,knee replacement surgery) at four to 48...econdary endpoint with Adlea demonstrating a highl...
...alize Colorectal Cancer Treatment Determining Who ...KS, Calif., Dec. 16 Amgen (Nasdaq: AMGN ) today ...f the KRAS gene as a predictive biomarker in pat...ated with anti-epidermal growth factor receptor (E....S. Food and Drug Administration,s (FDA) Oncologic...
Other Biology Technology:Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate 2Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 2Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 3Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 4Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 2Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 3Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 4Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 5Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 6Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 7Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 8
(Date:11/4/2009)...rstCall/ -- BIO-key International, Inc. (OTC Bulle...ic identification software is showcasing donor and...rence being held at the New Orleans Convention Cen...hands-on product demonstrations of its state-of-th...o, at 5 PM on Monday, October 26, Peter Lux, manag...
(Date:11/4/2009)...encoe Software, Inc., the commercial arm of the Op...://openmicroscopy.org ), is proud to announce its...iology,s exciting new project titled "The Cell: An... stimulus grant through the National Institutes of...rt of the American Reinvestment and Recovery Act, ...
(Date:11/3/2009)...published in a recent issue of HortTechnology , s...the effects of covering orchard floors with reflec...ight distribution, orchard temperature, and profit...nday and Solarmate films installed 5 weeks before ...pples. The research showed that the use of both fi...
Breaking Biology News(10 mins):BIO-key(R) International Exhibiting at AABB TXPO 2Glencoe Software to Support the ASCB 'Stimulus Grant' to Build Virtual Image Library of the Cell 2Reflective film can boost profits for apple growers 2China Medical Technologies Announces the Substantial Completion of an Independent Internal Investigation and Expected Timing of Reporting of Unaudited 53242 1China Medical Technologies Announces the Substantial Completion of an Independent Internal Investigation and Expected Timing of Reporting of Unaudited 53242 2China Medical Technologies Announces the Substantial Completion of an Independent Internal Investigation and Expected Timing of Reporting of Unaudited 53242 3China Medical Technologies Announces the Substantial Completion of an Independent Internal Investigation and Expected Timing of Reporting of Unaudited 53242 4Learning Takes Place When You Get Things Right 53240 1Learning Takes Place When You Get Things Right 53240 2The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 1The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 2
...anes, submarines and even automobiles of tomorrow ...rformance micro-mechanical gyroscopes for navigati...EMS gyroscope arrays being developed by a team con...avrik of Oak Ridge National Laboratory is radicall... and costly. Instead, this system consists of mult...
...this summer where the tiger,s roar will meet birds...ll be heard next door to advanced sonar systems; w... the smashing falls of Antarctic ice shelves. , ...d to them -- will only be found at the Acoustics,0... Friday July 4, 2008 at the Palais des Congrs in P...
...r Medical Research, led by Jos Luis Milln, Ph.D., ... of enzyme replacement therapy to prevent hypophos...tic origin. This discovery lays the foundation fo...ckets is a softening of the bones that most common... from insufficient exposure to sunlight. Hypophosp...
Other Biology News:Story tips from the Department of Energy's Oak Ridge National Laboratory, June 2008 2Story tips from the Department of Energy's Oak Ridge National Laboratory, June 2008 3Potential therapy discovered for hypophosphatasia, a congenital form of rickets 2
Rabbit Anti-Bcl-G, C-Terminus Polyclonal Antibody, Unconjugated from AnaSpec
Rabbit Anti-Mouse sRANKL Antibody, Biotin Conjugated from Cell Sciences
Rabbit Anti-L-isoleucine Antibody, Unconjugated from QED Bioscience Inc.
Anti-TIMP-4 (Tissue Inhibitor of Metalloproteinases-4), Loop #3 Polyclonal Antibody, Unconjugated from CHEMICON
Biology Products: